Es­pe­ri­on eyes new com­mer­cial push for cho­les­terol-low­er­ing drugs af­ter big FDA la­bel ex­pan­sion

Es­pe­ri­on has se­cured ma­jor FDA la­bel ex­pan­sions for its two cho­les­terol-low­er­ing drugs, a reg­u­la­to­ry mile­stone that it says opens up a much big­ger mar­ket and “sig­nif­i­cant­ly re­duces pre­vi­ous­ly ex­ist­ing pre­scrib­ing lim­i­ta­tions.”

Nexle­tol and Nexl­izet are now ap­proved to pre­vent heart at­tacks and car­dio­vas­cu­lar pro­ce­dures in both pri­ma­ry and sec­ondary pre­ven­tion pa­tients, re­gard­less of statin use. Both pills con­tain be­mpe­doic acid, Es­pe­ri­on’s key as­set, with one be­ing a monother­a­py and the oth­er be­ing a com­bi­na­tion with an­oth­er cho­les­terol-low­er­ing drug, eze­tim­ibe.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER